Publiсations

Hartl A, Sieper J, Syrbe U, Listing J, Hermann KG, Rudwaleit M, Poddubnyy D.
Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial.
Arthritis Res Ther. 2017; 19(1):140.
Proft F, Schulze-Koops H, Grunke M, Schrezenmeier E, Halleck F, Henes J, Unger L, Schmidt E, Fiehn C, Jacobi A, Iking-Konert C, Kneitz C, Schmidt RE, Bannert B, Voll RE, Fischer-Betz R, Kötter I, Tony HP, Holle J, Aringer M, Erler A, Behrens F, Burmester GR, Dörner T.
Sicherheit und Wirksamkeitshinweise zum Off-label-Einsatz von Biologikatherapien nach Versagen konventioneller Therapien bei Patienten mit entzündlich rheumatischen Erkrankungen.
Z Rheumatol. 2017; :doi: 10.1007/s00393-017-0330-4..
Proft F, Fleck M, Fiehn C, Schulze-Koops H, Witt M, Dörner T, Henes JC.
Wirksamkeits- und Sicherheitsanalyse von Off-label-Biologikatherapien bei Patienten mit autoinflammatorischen Erkrankungen.
Z Rheumatol. 2017; :doi: 10.1007/s00393-017-0329-x. [Epub ahead of print].
Wei JC, Baeten D, Sieper J, Deodhar A, Bhosekar V, Martin R, Porter B.
Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
Int J Rheum Dis. 2017; 20(5):589-596.
Szilagyi BA, Triebus J, Kressler C, de Almeida M, Tierling S, Durek P, Mardahl M, Szilagyi A, Floess S, Huehn J, Syrbe U, Walter J, Polansky JK, Hamann A.
Rituximab zur Behandlung von Poly- und Dermatomyositis.
Z Rheumatol. 2017; :doi: 10.1007/s00393-017-0327-z. [Epub ahead of print].
Henes JC, Schulze-Koops H, Witt M, Tony HP, Mueller F, Grunke M, Czihal M, Dörner T, Proft F.
Off-label-Biologikatherapie bei Patienten mit Großgefäßvaskulitiden und/oder Polymyalgia rheumatica.
Z Rheumatol. 2017; :doi: 10.1007/s00393-017-0325-1. [Epub ahead of print].
van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A.
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
Rheumatology (Oxford). 2017; :doi: 10.1093/rheumatology/kex174. [Epub ahead of print].
Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Lenaerts J, van den Bosch F, Wei JC, Pedersen R, Bonin R, Jones H, Marshall L, Logeart I, Vlahos B, Bukowski JF, Maksymowych WP.
Effects of Long-term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Results From the EMBARK Study..
Arthritis Care Res (Hoboken). 2017; :doi: 10.1002/acr.23276. [Epub ahead of print].
Weiß A, Minden K, Listing J, Foeldvari I, Sieper J, Rudwaleit M.
Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC..
RMD Open. 2017; 3(1):e000366.
Baraliakos X, Sieper J, Chen S, Pangan AL, Anderson JK.
Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time..
Rheumatology (Oxford). 2017; :doi: 10.1093/rheumatology/kex081. [Epub ahead of print].
Heftdal LD, Andersen T, Jæhger D, Woetmann A, Østgård R, Kenngott EE, Syrbe U, Sieper J, Hvid M, Deleuran B, Kragstrup TW.
Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis..
J Mol Med (Berl). 2017; 95(7):779-787.
Mease PJ, Van den Bosch F, Sieper J, Xia Y, Pangan AL, Song IH.
Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab..
J Rheumatol. 2017; 44(5):599-608.
Diekhoff T, Hermann KA, Greese J, Schwenke C, Poddubnyy D, Hamm B, Sieper J.
Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study.
Ann Rheum Dis. 2017; :doi: 10.1136/annrheumdis-2016-210640 [Epub ahead of print].
Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B; MEASURE 2 STUDY GROUP.
Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study..
Arthritis Care Res (Hoboken). 2017; :doi: 10.1002/acr.23233. [Epub ahead of print].
Szilagyi BA, Triebus J, Kressler C, de Almeida M, Tierling S, Durek P, Mardahl M, Szilagyi A, Floess S, Huehn J, Syrbe U, Walter J, Polansky JK, Hamann A.
Gut memories do not fade: epigenetic regulation of lasting gut homing receptor expression in CD4+ memory T cells.
Mucosal Immunol. 2017; :doi: 10.1038/mi.2017.7. [Epub ahead of print].
Sieper J, Poddubnyy D.
Axial spondyloarthritis.
Lancet 2017; :doi: 10.1016/S0140-6736(16)31591-4 [Epub ahead of print].
van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J.
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
Ann Rheum Dis. 2017; 76(6):978-991.
Poddubnyy D.
Radiographic Evaluation of Sacroiliac Joints in Axial Spondyloarthritis - Still Worth Performing?.
J Rheumatol. 2017; 44(1):1-3.
Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB; MEASURE 1 study group
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
Ann Rheum Dis. 2016; 76(6):1070-1077.
Kiltz U, Rudwaleit M, Sieper J, Braun J.
Evidenzbasierte Empfehlung zur Diagnostik und Therapie der axialen Spondyloarthritis.
Z Rheumatol. 2016; 76(2):111-117.
Braun J, Sieper J.
Low progression rate to ankylosing spondylitis (AS) in patients with presumable non-radiographic axial spondyloarthritis (nr-axSpA).
Arthritis Rheumatol 2016; 69(3):676-677.
Sieper J.
New treatment targets for axial spondyloarthritis.
J Immunol. 2016; 55(Suppl.2):ii38-ii42.
Sieper J, Hu X, Black CM, Grootscholten K, van den Broek RW, Kachroo S.
Systematic review of clinical, humanistic, and economic outcome comparisons between radiographic and non-radiographic axial spondyloarthritis.
Semin Arthritis Rheum. 2016; 46(6):746-753.
Durek P, Nordström K, Gasparoni G, Salhab A, Kressler C, de Almeida M, Bassler K, Ulas T, Schmidt F, Xiong J, Glažar P, Klironomos F, Sinha A, Kinkley S, Yang X, Arrigoni L, Amirabad AD, Ardakani FB, Feuerbach L, Gorka O, Ebert P, Müller F, Li N, Frischbutter S, Schlickeiser S, Cendon C, Fröhler S, Felder B, Gasparoni N, Imbusch CD, Hutter B, Zipprich G, Tauchmann Y, Reinke S, Wassilew G, Hoffmann U, Richter AS, Sieverling L; DEEP Consortium., Chang HD, Syrbe U, Kalus U, Eils J, Brors B, Manke T, Ruland J, Lengauer T, Rajewsky N, Chen W, Dong J, Sawitzki B, Chung HR, Rosenstiel P, Schulz MH, Schultze JL, Radbruch A, Walter J, Hamann A, Polansky JK.
Epigenomic Profiling of Human CD4+ T Cells Supports a Linear Differentiation Model and Highlights Molecular Regulators of Memory Development.
Immunity. 2016; 45(5):1148-1161.
Poddubnyy D, Fedorova A, Listing J, Haibel H, Baraliakos X, Braun J, Sieper J.
Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
J Rheumatol. 2016; 43(12):2142-2148.
Thomas GP, Willner D, Robinson PC, Cortes A, Duan R, Rudwaleit M, Akkoc N, Braun J, Chou CT, Maksymowych WP, Ozgocmen S, Roussou E, Sieper J, Valle-Oñate R, van der Heijde D, Wei J, Leo P, Brown MA; and the International Genetics of Ankylosing Spondylitis Consortium.
Genetic diagnostic profiling in axial spondyloarthritis: a real world study.
Clin Exp Rheumatol. 2016; 35(2):229-233.
Sieper J, Holbrook T, Black CM, Wood R, Hu X, Kachroo S.
Burden of illness associated with non-radiographic axial spondyloarthritis: a multiperspective European cross-sectional observational study.
Clin Exp Rheumatol. 2016; 34(6):975-983.
Balazcs E, Sieper J, Bickham K, Mehta A, Frontera N, Stryszak P, Popmihajlov Z, Peloso PM.
A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis.
BMC Musculoskelet Disord. 2016; 13(1):426.
van der Heijde D, Deodhar A, Fleischmann R, Mease PJ, Rudwaleit M, Nurminen T, Davies BPharm O.
Early Disease Activity or Clinical Response Predict Long-Term Outcomes with Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.
Arthritis Care Res (Hoboken). 2016; :doi: 10.1002/acr.23092. [Epub ahead of print].
Rudwaleit M, Landewé R, Sieper J.
Ankylosing Spondylitis and Axial Spondyloarthritis.
N Engl J Med. 2016; 375(13):1302-1303.
Pink M, Ratsch BA, Mardahl M, Durek P, Polansky JK, Karl M, Baumgrass R, Wallner S, Cadenas C, Gianmoena K, Floess S, Chen W, Nordstroem K, Tierling S, Olek S, Walter J, Hamann A, Syrbe U.
Imprinting of Skin/Inflammation Homing in CD4+ T Cells Is Controlled by DNA Methylation within the Fucosyltransferase 7 Gene.
J Immunol. 2016; 197(8):3406-3414.
Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, Andersson M, Porter B, Richards HB; MEASURE 2 Study Group.
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
Ann Rheum Dis. 2016; 76(3):571-592.
Mardahl M, Schröter MF, Engelbert D, Pink M, Sperandio M, Hamann A, Syrbe U.
Core 2 ß1,6-N-acetylglucosaminyltransferase-I, crucial for P-selectin ligand expression is controlled by a distal enhancer regulated by STAT4 and T-bet in CD4+ T helper cells 1.
Mol Immunol. 2016; (77):132-140.
Baraliakos X, Heldmann F, van den Bosch F, Burmester G, Gaston H, van der Horst-Bruinsma IE, Krause A, Schmidt R, Schneider M, Sieper J, Andermann B, van Tubergen A, Witt M, Braun J.
Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction.
RMD Open 2016; 2(2):e000272.
U. Kiltz, J. Sieper, M. Backhaus, B. Buss, E. Gromnica-Ihle, H. Haíbel, L. Hammel, K. Karberg, S. Rehart, M. Rudwaleit, F. Schuch, P. Steffens-Korbanka, J. Braun
„Treat-to-target (T2T)“ Empfehlungen für die Behandlung von Patienten mit Spondyloarthritis – Übersetzung ins Deutsche.
Z Rheumatol. 2016; 75(9):903-909.
Sieper J, Rudwaleit M, Lenaerts J, Wollenhaupt J, Myasoutova L, Park SH, Song YW, Yao R, Huyck S, Govoni M, Chitkara D, Vastesaeger N.
Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
Rheumatology (Oxford) 2016; 55(11):1946-1953.
Rudwaleit M.
Spondyloarthropathies: Identifying axial SpA in young adults with chronic back pain..
Nat Rev Rheumatol. 2016; 12(7):378-380.
Bleil J, Maier R, Hempfing A, Sieper J, Appel H, Syrbe U.
Granulation tissue eroding the subchondral bone also promotes new bone formation in ankylosing spondylitis.
Arthritis Rheumatol. 2016; 68(10):2456-2465.
Sieper J, Poddubnyy D.
New evidence on the management of spondyloarthritis.
Nat Rev Rheumatol. 2016; 12(5):282-295.
Heldmann F, Baraliakos X, Kiltz U, Brandt J, van der Horst-Bruinsma IE, Landewé R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Gaston H, Gruenke M, Witt M, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Braun J.
Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety.
Clin Exp Rheumatol 2016; 34(2):184-90.
Braun J, Bessler F, Lakomek HJ, Rudwaleit M.
Internationale Qualitätsindikatoren in der Rheumatologie. Vorschläge für die rheumatoide Arthritis.
Z Rheumatol. 2016; 75(3):330-337.
Sepriano A, Rudwaleit M, Sieper J, van den Berg R, Landewé R, van der Heijde D.
Five-year follow-up of radiographic sacroiliitis: progression as well as improvement?.
Ann Rheum Dis. 2016; 75(6):1262-1263.
Sepriano A, Landewé R, van der Heijde D, Sieper J, Akkoc N, Brandt J, Braun J, Collantes-Estevez E, Dougados M, Fitzgerald O, Huang F, Gu J, Kirazli Y, Maksymowych WP, Marzo-Ortega H, Olivieri I, Ozgocmen S, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Van den Bosch F, van der Horst-Bruinsma I, Weber U, Wei J, Rudwaleit M; ASAS.
Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis.
Ann Rheum Dis. 2016; 75(6):1034-1042.
Althoff CE, Sieper J, Song IH, Weiß A, Diekhoff T, Haibel H, Hamm B, Hermann KG.
Comparison of Clinical Examination versus Whole-body Magnetic Resonance Imaging of Enthesitis in Patients with Early Axial Spondyloarthritis during 3 Years of Continuous Etanercept Treatment.
J Rheumatol. 2016; 43(3):618-624.
Rudwaleit M, Rosenbaum JT, Landewé R, Marzo-Ortega H, Sieper J, van der Heijde D, Davies O, Bartz H, Hoepken B, Nurminen T, Deodhar A.
Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis.
Arthritis Care Res (Hoboken). 2016; 68(6):838-844.
Hammoudeh M, Abdulaziz S, Alosaimi H, Al-Rayes H, Aldeen Sarakbi H, Baamer M, Baraliakos X, Dahou Makhloufi C, Janoudi N, Shirazy K, Sieper J, Sukhbir U.
Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: An expert consensus.
J Int Med Res. 2016; 44(2):216-230.
Atkinson SM, Bleil J, Maier R, Kühl AA, Thorn M, Serikawa K, Fox B, Kruse K, Haase C, Skov S, Nansen A, Syrbe U.
Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model.
Arthritis Res Ther. 2016; 18:28.
Rios Rodriguez V, Poddubnyy D.
Golimumab for treatment of axial spondyloarthritis.
Immunotherapy. 2016; 8(2):107-115.
Rios Rodriguez V, Poddubnyy D.
Etanercept for the treatment of non-radiographic axial spondyloarthritis.
Expert Rev Clin Immunol. 2016; 12(5):493-500.
Lambert RG, Bakker PA, van der Heijde D, Weber U, Rudwaleit M, Hermann KG, Sieper J, Baraliakos X, Bennett A, Braun J, Burgos-Vargas R, Dougados M, Pedersen SJ, Jurik AG, Maksymowych WP, Marzo-Ortega H, Østergaard M, Poddubnyy D, Reijnierse M, van den Bosch F, van der Horst-Bruinsma I, Landewé R.
Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.
Ann Rheum Dis. 2016; 75(11):1958-1963.
Song IH, Brenneis C, Hammel L, Feldtkeller E, Listing J, Sieper J, Rudwaleit M.
Ankylosing spondylitis self-help organisations - do members differ from non-members?.
Joint Bone Spine. 2016; 83(3):295-300.
Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D.
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Ann Rheum Dis. 2016; 75(3):499-510.
Rios Rodriguez V, Poddubnyy D.
Old and new treatment targets in axial spondyloarthritis..
RMD Open. 2016; 1(Suppl 1):e000054.
Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Weiß A, Freundlich B, Lange E, Rudwaleit M, Sieper J.
Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis-3-Year data of the ESTHER trial.
Semin Arthritis Rheum. 2016; 45(4):404-410.
Pedersen SJ, Poddubnyy D, Sørensen IJ, Loft AG, Hindrup JS, Thamsborg G, Asmussen K, Hendricks O, Nørregaard J, Piil AD, Møller JM, Jurik AG, Balding L, Lambert RG, Sieper J, Østergaard M.
Course of Magnetic Resonance Imaging-Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by....
Arthritis Rheumatol. 2016; 68(2):418-429.
Baraliakos X, Borah B, Braun J, Baeten D, Laurent D, Sieper J, Emery P, McInnes IB, van Laar JM, Wordsworth P, Wollenhaupt J, Kellner H, Colin L, Vandenhende F, Radford K, Hueber W.
Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study.
Ann Rheum Dis. 2016; 75(2):408-412.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group.
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
N Engl J Med. 2015; 373(26):2534-2548.
Appel H.
Dr. Appel replies.
J Rheumatol 2015; 42(11):2211.
Maksymowych WP, Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Van den Bosch F, Logeart I, Wajdula J, Jones H, Marshall L, Bonin R, Pedersen R, Vlahos B, Kotak S, Bukowski JF.
Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study.
Ann Rheum Dis. 2015; 75(7):1328-1335.
Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, Syrbe U, Braun J, Rudwaleit M.
Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS).
Ann Rheum Dis. 2015; 75(8):1438-1443.
Conrad K, Wu P, Sieper J, Syrbe U.
In vivo pre-activation of monocytes in patients with axial spondyloarthritis.
Arthritis Res Ther. 2015; 16(17):179.
Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, Berd Y, Bergman G, Curtis S, Tzontcheva A, Huyck S, Weng HH.
A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis..
Ann Rheum Dis. 2015; 67(10):2702-2712.
Bleil J, Sieper J, Maier R, Schlichting U, Hempfing A, Syrbe U, Appel H.
Cartilage in facet joints of patients with ankylosing spondylitis (AS) shows signs of cartilage degeneration rather than chondrocyte hypertrophy: implications for joint remodeling in AS..
Arthritis Res Ther. 2015; 17(17):170.
Mease P, Sieper J, Van den Bosch F, Rahman P, Pangan A.
Reply: To PMID 25545240.
Arthritis Rheumatol. 2015; 67(10):2793-2794.
Poddubnyy D, van Tubergen A, Landewé R, Sieper J, van der Heijde D; Assessment of SpondyloArthritis international Society (ASAS).
Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis.
Ann Rheum Dis. 2015; 74(8):1483-1487.
Bleil J, Maier R, Syrbe U, Sieper J, Appel H.
In situ analysis of interleukin-6 expression at different sites of zygapophyseal joints from patients with ankylosing spondylitis in comparison to controls..
Scand J Rheumatol. 2015; 44(4):296-301.
Haibel H, Sieper J.
Enthesitis im Rahmen von Spondyloarthritiden.
Orthopade. 2015; 44(5):395-404.
Mandl P, Navarro-Compán V, Terslev L, Aegerter P, van der Heijde D, D'Agostino MA, Baraliakos X, Pedersen SJ, Jurik AG, Naredo E, Schueller-Weidekamm C, Weber U, Wick MC, Bakker PA, Filippucci E, Conaghan PG, Rudwaleit M, Schett G, Sieper J, Tarp S, Marzo-Ortega H, Østergaard M; European League Against Rheumatism (EULAR).
EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice.
Ann Rheum Dis. 2015; 74(7):1327-1339.
Appel H, Sieper J.
Analysis of bone samples from patients with spondyloarthritides-identifying causes of new bone formation in axial spondyloarthritis..
J Rheumatol. 2015; 42(4):561-563.
Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, Landewé R.
Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
Arthritis Care Res (Hoboken). 2015; 67(10):1475-1480.
Sieper J, Braun J.
Erfahrungen aus 15 Jahren Investigator-initiierten klinischen Studien zur axialen Spondyloarthritis.
Z Rheumatol. 2015; 74(2):125-131.
Sieper J, Braun J.
Von der Ungewissheit zur Evidenz.
Z Rheumatol. 2015; 74(2):104-105.
Haibel H, Sieper J.
Enthesitis im Rahmen von Spondyloarthritiden.
Z Rheumatol. 2015; 74(1):39-48.
Mease P, Sieper J, Van den Bosch F, Rahman P, Karunaratne PM, Pangan AL.
Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.
Arthritis Rheumatol. 2015; 67(4):914-923.
van der Heijde D, Breban M, Halter D, DiVittorio G, Bratt J, Cantini F, Kary S, Pangan AL, Kupper H, Rathmann SS, Sieper J, Mease PJ.
Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
Rheumatology (Oxford). 2015; 54(7):1210-1219.
Boonen A, Sieper J, van der Heijde D, Dougados M, Bukowski JF, Valluri S, Vlahos B, Kotak S.
The burden of non-radiographic axial spondyloarthritis..
Semin Arthritis Rheum. 2015; 44(5):556-562.
Poddubnyy D, Gensler LS.
Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis..
Best Pract Res Clin Rheumatol. 2015; 28(5):807-818.
Haftmann C, Stittrich AB, Zimmermann J, Fang Z, Hradilkova K, Bardua M, Westendorf K, Heinz GA, Riedel R, Siede J, Lehmann K, Weinberger EE, Zimmel D, Lauer U, Häupl T, Sieper J, Backhaus M, Neumann C, Hoffmann U, Porstner M, Chen W, Grün JR, Baumgrass R, Matz M, Löhning M, Scheffold A, Wittmann J, Chang HD, Rajewsky N, Jäck HM, Radbruch A, Mashreghi MF.
miR-148a is upregulated by Twist1 and T-bet and promotes Th1-cell survival by regulating the proapoptotic gene Bim..
Eur J Immunol. 2015; 45(4):1192-1205.
Sieper J, Landewé R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, Braun J, Deodhar A, Kivitz A, Walsh J, Hoepken B, Nurminen T, Maksymowych WP.
Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
Arthritis Rheumatol. 2015; 67(3):668-677.
Deodhar A, Sieper J, Reveille JD, van der Heijde D, Gensler LS, Landewé R; Spondyloarthritis Research and Treatment Network and Assessment of SpondyloArthritis international Society authors.
Reply: To PMID 25154344.
Arthritis Rheumatol. 2015; 67(3):856-857.
Syrbe U, Callhoff J, Conrad K, Poddubnyy D, Haibel H, Junker S, Frommer KW, Müller-Ladner U, Neumann E, Sieper J.
Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression.
Arthritis Rheumatol. 2015; 67(3):678-685.
Braun J, Baraliakos X, Kiltz U, Heldmann F, Sieper J.
Classification and diagnosis of axial spondyloarthritis--what is the clinically relevant difference?.
J Rheumatol. 2015; 42(1):31-38.
Syrbe U, Siegmund B.
Bone marrow Th17 TNFα cells induce osteoclast differentiation and link bone destruction to IBD.
Gut. 2015; 64(7):1011-1012.
Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Weiß A, Lange E, Freundlich B, Rudwaleit M, Sieper J.
Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial.
Rheumatology (Oxford). 2015; 54(2):257-261.
Callhoff J, Sieper J, Weiß A, Zink A, Listing J.
Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Ann Rheum Dis. 2015; 74(6):1241-1248.
Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, Fiore S, Momtahen T, Yancopoulos GD, Stahl N, Inman RD.
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).
Ann Rheum Dis. 2015; 74(6):1051-1057.
Moltó A, Paternotte S, van der Heijde D, Claudepierre P, Rudwaleit M, Dougados M.
Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort.
Ann Rheum Dis. 2015; 74(4):746-751.
van der Heijde D, Sieper J, Elewaut D, Deodhar A, Pangan AL, Dorr AP.
Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis: results of an international survey.
J Clin Rheumatol. 2014; 20(8):411-417.
Kiltz U, Sieper J, Kellner H, Krause D, Rudwaleit M, Chenot JF, Stallmach A, Jaresch S, Braun J; German Society for Rheumatology.
DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen. DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen: 8.4 Medikamentöse Therapie, 8.5 Evaluation des Therapieerfolgs medikamentöser...
Z Rheumatol. 2014; 73(Suppl 2):78-96.
Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Böhle E, Böhm H, Böhncke WH, Chenot JF, Heiligenhaus A, Jaresch S, Mau W, Oberschelp U, Pleyer U, Repschläger U, Schneider E, Smolenski U, Stallmach A, Stemmer M, Swoboda B, Ulrich C, Winking M, Braun J; German Society for Rheumatology.
DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen: 8 Therapie, 8.1 Behandlungskonzept, 8.2 Therapieziele und -strategie.
Z Rheumatol. 2014; 73(Suppl 2):69-70.
Kiltz U, Rudwaleit M, Sieper J, Krause D, Oberschelp U, Schneider E, Swoboda B, Böhm H, Braun J; German Society for Rheumatology.
DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen: 7 Krankheitsaktivität und Prognose der SpA.
Z Rheumatol. 2014; 73(Suppl 2):66-68.
Kiltz U, Rudwaleit M, Sieper J, Krause D, Hermann KG, Braun J; German Society for Rheumatology.
DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen: 6 Diagnostik.
Z Rheumatol. 2014; 73(Suppl 2):49-65.
Kiltz U, Rudwaleit M, Sieper J, Krause D, Heiligenhaus A, Pleyer U, Chenot JF, Stallmach A, Jaresch S, Oberschelp U, Schneider E, Swoboda B, Böhm H, Hermann KG, Böhncke WH, Braun J; German Society for Rheumatology.
DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen: 5 Erstdiagnose/Überweisungsstrategie.
Z Rheumatol. 2014; 73(Suppl 2):44-48.
Kiltz U, Rudwaleit M, Sieper J, Braun J; German Society for Rheumatology.
DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen: 4 Klassifikations- und Diagnosekriterien.
Z Rheumatol. 2014; 73(Suppl 2):40-43.
Kiltz U, Rudwaleit M, Sieper J, Krause D, Chenot JF, Stallmach A, Jaresch S, Oberschelp U, Schneider E, Swoboda B, Böhm H, Heiligenhaus A, Pleyer U, Böhncke WH, Stemmer M, Braun J; German Society for Rheumatology.
DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen: 3 Klinische Symptomatik.
Z Rheumatol. 2014; 73(Suppl 2):28-39.
Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Böhle E, Böhm H, Böhncke WH, Chenot JF, Heiligenhaus A, Hermann KG, Jaresch S, Mau W, Oberschelp U, Pleyer U, Repschläger U, Schneider E, Smolenski U, Stallmach A, Stemmer M, Swoboda B, Ulrich C, Winking M, Braun J; German Society for Rheumatology.
DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen: 2 Präambel.
Z Rheumatol. 2014; 73(Suppl 2):26-27.
Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Böhle E, Böhm H, Böhncke WH, Chenot JF, Heiligenhaus A, Hermann KG, Jaresch S, Mau W, Oberschelp U, Pleyer U, Repschläger U, Schneider E, Smolenski U, Stallmach A, Stemmer M, Swoboda B, Ulrich C, Winking M, Braun J; German Society for Rheumatology.
DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen: 1 Einleitung/Vorbemerkung.
Z Rheumatol. 2014; 73(Suppl 2):23-25.
Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos-Vargas R, Caplan L, Clegg DO, Colbert RA, Gensler LS, van der Heijde D, van der Horst-Bruinsma IE, Inman RD, Maksymowych WP, Mease PJ, Raychaudhuri S, Reimold A, Rudwaleit M, Sieper J, Weisman MH, Landewé RB.
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns.
Arthritis Rheumatol. 2014; 66(10):2649-56.
Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Weiß A, Buß B, Freundlich B, Lange E, Alten R, Rudwaleit M, Sieper J.
Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial.
J Rheumatol. 2014; 41(10):2034-2040.
Pink M, Ratsch BA, Mardahl M, Schröter MF, Engelbert D, Triebus J, Hamann A, Syrbe U.
Identification of two regulatory elements controlling Fucosyltransferase 7 transcription in murine CD4+ T cells.
Mol Immunol. 2014; 62(1):1-9.
Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, Miceli-Richard C, Wei JC, Pedersen R, Bonin R, Rahman MU, Logeart I, Wajdula J, Koenig AS, Vlahos B, Alvarez D, Bukowski JF.
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis Rheumatol. 2014; 66(8):2091-2102.
Turina MC, Sieper J, Yeremenko N, Conrad K, Haibel H, Rudwaleit M, Baeten D, Poddubnyy D.
Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis.
Ann Rheum Dis. 2014; 73(9):1746-1748.
Sieper J, Poddubnyy D.
Inflammation, new bone formation and treatment options in axial spondyloarthritis.
Ann Rheum Dis. 2014; 73(8):1439-1441.
Poddubnyy D, Sieper J.
Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment.
Curr Opin Rheumatol. 2014; 26(4):377-383.
Becker H, Appel H, Fassbinder T, Heitzmann D, Willeke P, Jacobi AM.
Rituximab zur Therapie des Felty-Syndroms.
Z Rheumatol. 2014; 73(5):465-466.
Bleil J, Maier R, Hempfing A, Schlichting U, Appel H, Sieper J, Syrbe U.
Histomorphologic and histomorphometric characteristics of zygapophyseal joint remodeling in ankylosing spondylitis.
Arthritis Rheumatol. 2014; 66(7):1745-1754.
van der Heijde D, Sieper J, Maksymowych WP, Brown MA, Lambert RG, Rathmann SS, Pangan AL.
Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis.
Arthritis Rheumatol. 2014; 66(3):667-673.
Krohn M, Braum LS, Sieper J, Song IH, Weiss A, Callhoff J, Althoff CE, Hamm B, Hermann KG.
Erosions and fatty lesions of sacroiliac joints in patients with axial spondyloarthritis: evaluation of different MRI techniques and two scoring methods.
J Rheumatol. 2014; 41(3):473-480.
Sieper J.
Response to H Zeidler's comments on the INFAST study.
Ann Rheum Dis. 2014; 73(4):e19.
Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J.
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).
Ann Rheum Dis. 2014; 73(5):817-823.
Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, van der Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville M, Sieper J.
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
Ann Rheum Dis. 2014; 73(1):39-47.
Poddubnyy D, Conrad K, Haibel H, Syrbe U, Appel H, Braun J, Rudwaleit M, Sieper J.
Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis.
Ann Rheum Dis. 2014; 73(12):2137-2143.
Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Grunke M, Van Der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, Van Der Heijde D, Braun J.
Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography.
Ann Rheum Dis. 2014; 73(10):1819-1825.
Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M.
Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials.
Ann Rheum Dis. 2014; 73(1):95-100.
Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Schoels M, Sieper J, Wit Md, Baraliakos X, Betteridge N, Burgos-Vargas R, Collantes-Estevez E, Deodhar A, Elewaut D, Gossec L, Jongkees M, Maccarone M, Redlich K, van den Bosch F, Wei JC, Winthrop K, van der Heijde D.
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force..
Ann Rheum Dis. 2014; 73(1):6-16.
Schoels MM, Braun J, Dougados M, Emery P, Fitzgerald O, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Sieper J, Smolen JS, Wit Md, van der Heijde D.
Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis..
Ann Rheum Dis. 2014; 73(1):238-242.
Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, Chitkara D, Vastesaeger N; All INFAST Investigators.
Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2.
Ann Rheum Dis. 2014; 73(1):108-113.
Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, Chitkara D, Vastesaeger N; All INFAST Investigators.
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1.
Ann Rheum Dis. 2014; 73(1):101-107.
Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, Reuter S, Matthias T, Schmidt RE, Witte T.
Autoantibodies against CD74 in spondyloarthritis.
Ann Rheum Dis. 2014; 73(6):1211-1214.
Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J.
Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial.
Ann Rheum Dis. 2014; 73(1):243-246.
Baraliakos X, Haibel H, Listing J, Sieper J, Braun J.
Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis..
Ann Rheum Dis. 2014; 73(4):710-715.
McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP.
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
Ann Rheum Dis. 2014; 73(2):349-356.
Song IH, Rudwaleit M
Certolizumab pegol in axial spondyloarthritis.
Expert Rev Clin Immunol. 2013; 9(12):1161-72.
Baraliakos X, Kiltz U, Heldmann F, Sieper J, Braun J.
Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease.
Clin Exp Rheumatol. 2013; 31(4 Suppl 78):S43-46.
Song IH, Haibel H, Poddubnyy D, Braun J, Sieper J.
Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease.
Clin Exp Rheumatol. 2013; 31(4 Suppl 78):S37-42.
Braun J, Sieper J.
Remission and possible discontinuation of biological therapy in axial spondyloarthritis.
Clin Exp Rheumatol. 2013; 31(4 Suppl 78):S33-36.
Polansky JK, Syrbe U, Hamann A.
Epigenetische Analysen – neue Ansätze für die Therapie rheumatischer Erkrankungen?.
Z Rheumatol. 2013; 72(8):804-808.
Poddubnyy D, Rudwaleit M.
Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update..
Expert Opin Biol Ther. 2013; 13(11):1599-1611.
Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W.
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Lancet. 2013; 382(9906):1705-1713.
Feldtkeller E, Lind-Albrecht G, Rudwaleit M.
Kernsatz von Verhaltensempfehlungen für Patienten mit ankylosierender Spondylitis.
Z Rheumatol. 2013; 72(10):993-996.
Baraliakos X, Listing J, Haibel H, Sieper J, Braun J.
Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: changes after 2 years of tumor necrosis factor inhibitor therapy.
J Rheumatol. 2013; 40(11):1891-1896.
Sieper J.
Treatment challenges in axial spondylarthritis and future directions.
Curr Rheumatol Rep. 2013; 15(9):356.
Poddubnyy D, Gaydukova I, Hermann KG, Song IH, Haibel H, Braun J, Sieper J.
Magnetic resonance imaging compared to conventional radiographs for detection of chronic structural changes in sacroiliac joints in axial spondyloarthritis..
J Rheumatol. 2013; 40(9):1557-1565.
Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J.
Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.
Arthritis Res Ther. 2013; 15(3):R67.
Haibel H, Heldmann F, Braun J, Listing J, Kupper H, Sieper J.
Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare.
Arthritis Rheum. 2013; 65(8):2211-2213.
Hoffmann U, Pink M, Lauer U, Heimesaat MM, Winsauer C, Kruglov A, Schlawe K, Leichsenring C, Liesenfeld O, Hamann A, Syrbe U.
Regulation and migratory role of P-selectin ligands during intestinal inflammation.
PLoS One. 2013; 8(4):e62055.
Poddubnyy D, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J, Rudwaleit M.
Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC)..
Ann Rheum Dis. 2013; 72(8):1430-1432.
Moltó A, Paternotte S, Comet D, Thibout E, Rudwaleit M, Claudepierre P, van der Heijde D, Dougados M.
Performances of the Assessment of SpondyloArthritis International Society axial spondyloarthritis criteria for diagnostic and classification purposes in patients visiting a rheumatologist because of chronic back pain: results from a multicenter....
Arthritis Care Res (Hoboken). 2013; 65(9):1472-1481.
Feldtkeller E, Lind-Albrecht G, Rudwaleit M.
Core set of recommendations for patients with ankylosing spondylitis concerning behaviour and environmental adaptations.
Ann Rheum Dis. 2013; 33(9):2343-2349.
Furst DE, Fleischman R, Kalden J, Kavanaugh A, Sieper J, Mease P, Smolen J, Breedveld F.
Documentation of off-label use of biologics in Rheumatoid Arthritis..
Ann Rheum Dis. 2013; 72(Suppl 2):ii35-51.
Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop KL.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.
Ann Rheum Dis. 2013; 72(Suppl 2):ii2-34.
Poddubnyy D.
Axial spondyloarthritis: is there a treatment of choice?.
Ther Adv Musculoskelet Dis. 2013; 5(1):45-54.
Appel H, Maier R, Bleil J, Hempfing A, Loddenkemper C, Schlichting U, Syrbe U, Sieper J.
In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis.
Arthritis Rheum. 2013; 65(6):1522-1529.
Kiltz U, Sieper J, Braun J.
ASAS-Empfehlungen zur Anwendung von TNF-Blockern bei Patienten mit axialer Spondyloarthritis. Evaluation des Updates von 2010 im deutschsprachigen Raum.
Z Rheumatol. 2013; 72(1):81-88.
Baeten D, Breban M, Lories R, Schett G, Sieper J.
Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype?.
Arthritis Rheum. 2013; 65(1):12-20.
Dong J, Chang HD, Ivascu C, Qian Y, Rezai S, Okhrimenko A, Cosmi L, Maggi L, Eckhardt F, Wu P, Sieper J, Alexander T, Annunziato F, Gossen M, Li J, Radbruch A, Thiel A.
Loss of methylation at the IFNG promoter and CNS-1 is associated with the development of functional IFN-γ memory in human CD4(+) T lymphocytes.
Eur J Immunol. 2013; 43(3):793-804.
Rudwaleit M.
The impact of cohort studies in spondyloarthritis.
Joint Bone Spine. 2013; 80(2):127-129.
Sieper J, van der Heijde D.
Review: Nonradiographic axial spondyloarthritis: new definition of an old disease?.
Arthritis Rheum. 2013; 65(3):543-551.
Kiltz U, Sieper J, Braun J.
Empfehlungen für die Behandlung der ankylosierenden Spondylitis gemäß ASAS/EULAR. Evaluation der Updates von 2010 im deutschsprachigen Raum.
Z Rheumatol. 2013; 72(1):71-80.
Song IH, Weiß A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Lange E, Freundlich B, Rudwaleit M, Sieper J.
Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial.
Ann Rheum Dis. 2013; 72(6):832-835.
van den Berg R, de Hooge M, Rudwaleit M, Sieper J, van Gaalen F, Reijnierse M, Landewé R, Huizinga T, van der Heijde D.
ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort..
Ann Rheum Dis. 2013; 72(10):1646-1653.
Sieper J, Srinivasan S, Zamani O, Mielants H, Choquette D, Pavelka K, Loft AG, Géher P, Danda D, Reitblat T, Cantini F, Ancuta C, Erdes S, Raffayová H, Keat A, Gaston JS, Praprotnik S, Vastesaeger N.
Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study.
Ann Rheum Dis. 2013; 72(10):1621-1627.
Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Haug-Rost I, Braun J, Sieper J.
One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare.
Ann Rheum Dis. 2013; 72(6):305-306.
Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, Pangan AL.
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
Ann Rheum Dis. 2013; 72(6):815-822.
Althoff CE, Sieper J, Song IH, Haibel H, Weiß A, Diekhoff T, Rudwaleit M, Freundlich B, Hamm B, Hermann KG.
Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI.
Ann Rheum Dis. 2013; 72(6):967-973.